CareDx Inc

CareDx CFO/COO buys 24,134 restricted shares, boosting his stake as the company’s stock surges 17%—a bullish insider move amid new AlloSeq Nano platform growth.

CareDx insider sales spark debate over management confidence, reflecting strategic shift to transplant‑monitoring amid market volatility and a $170 M EuroBio divestiture.

CareDx insider buying shows leadership confidence ahead of AlloHeme™ validation, tying executive equity to future milestones and market‑access success.